Growth factors contribute to the mediation of angiogenic capacity of glioma‑associated mesenchymal stem cells

Zhang,Qing; Xiang,Wei; Xue,Bing-Zhou; Yi,Dong-Ye; Zhao,Hong-Yang; Fu,Peng

doi:10.3892/ol.2021.12476

Growth factors contribute to the mediation of angiogenic capacity of glioma‑associated mesenchymal stem cells

Authors:
- Qing Zhang
- Wei Xiang
- Bing-Zhou Xue
- Dong-Ye Yi
- Hong-Yang Zhao
- Peng Fu
View Affiliations

Affiliations: Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: January 19, 2021 https://doi.org/10.3892/ol.2021.12476
Article Number: 215
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) are important components of stromal cell populations and serve a crucial role in tumor growth and progression. Previously, our laboratory successfully isolated and cultured MSCs from human glioma issues and demonstrated that glioma‑associated mesenchymal stem cells (gb‑MSCs) participate in and maintain tumor angiogenesis. Furthermore, growth factors, such as fibroblast growth factor and vascular endothelial cell growth factor, were demonstrated to be associated with endothelial cell tube formation. However, the effect of transforming growth factor β1 (TGF‑β1) and platelet‑derived growth factor‑BB (PDGF‑BB) on the angiogenic activity of gb‑MSCs remains unknown. The present study aimed therefore to explore their effects in gb‑MSCs angiogenesis. In the present study, gb‑MSCs were isolated from patients with glioma and were characterized using flow cytometry and differentiation experiments. Furthermore, the results from tube formation assay revealed that TGF‑β1 and PDGF‑BB could mediate the angiogenic capacity of gb‑MSCs in vitro. In addition, results from immunofluorescence demonstrated that gb‑MSCs expressed TGF‑β1R and PDGFR, which are the receptors for TGF‑β1 and PDGF‑BB, respectively. Taken together, these findings indicated that TGF‑β1 and PDGF‑BB may serve a crucial role in mediating gb‑MSC angiogenesis, which might provide a therapeutic strategy for targeting the angiogenic capacity of gb‑MSCs in patients with glioma.

View Figures

View References

1	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
2	Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY and Wei X: Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 4:833–838. 2016. View Article : Google Scholar : PubMed/NCBI
3	Holland EC: Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA. 97:6242–6244. 2000. View Article : Google Scholar : PubMed/NCBI
4	Surawicz TS, Davis F, Freels S, Laws ER Jr and Menck HR: Brain tumor survival: Results from the national cancer data base. J Neurooncol. 40:151–160. 1998. View Article : Google Scholar : PubMed/NCBI
5	DeAngelis LM: Brain tumors. N Engl J Med. 344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, et al: Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6/gp130/STAT3 pathway. Stem Cells. 33:2400–2415. 2015. View Article : Google Scholar : PubMed/NCBI
7	Zhang Q, Yi DY, Xue BZ, Wen WW, Lu YP, Abdelmaksou A, Sun MX, Yuan DT, Zhao HY, Xiong NX, et al: CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression. Cell Death Dis. 9:11012018. View Article : Google Scholar : PubMed/NCBI
8	Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP and Lang FF: Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 19:660–668. 2017.PubMed/NCBI
9	Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R and Straube A: Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol. 83:241–247. 2007. View Article : Google Scholar : PubMed/NCBI
10	Birnbaum T, Hildebrandt J, Nuebling G, Sostak P and Straube A: Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. J Neurooncol. 105:57–65. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yi D, Xiang W, Zhang Q, Cen Y, Su Q, Zhang F, Lu Y, Zhao H and Fu P: Human glioblastoma-derived mesenchymal stem cell to pericytes transition and angiogenic capacity in glioblastoma microenvironment. Cell Physiol Biochem. 46:279–290. 2018. View Article : Google Scholar : PubMed/NCBI
12	Kargiotis O, Rao JS and Kyritsis AP: Mechanisms of angiogenesis in gliomas. J Neurooncol. 78:281–293. 2006. View Article : Google Scholar : PubMed/NCBI
13	Keerl S, Gehmert S, Gehmert S, Song YH and Alt E: PDGF and bFGF modulate tube formation in adipose tissue-derived stem cells. Ann Plast Surg. 64:487–490. 2010. View Article : Google Scholar : PubMed/NCBI
14	Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ and Weller M: Transforming growth factor-β pathway activity in glioblastoma. Oncotarget. 6:5963–5977. 2015. View Article : Google Scholar : PubMed/NCBI
15	Liubich LD, Kovalevska L, Lisyany MI, Semenova VM, Malysheva TA, Stayno LP and Vaslovych VV: TGF-β1 expression by glioma C6 cells in vitro. Exp Oncol. 39:258–263. 2017. View Article : Google Scholar : PubMed/NCBI
16	Ferrari G, Cook BD, Terushkin V, Pintucci G and Mignatti P: Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol. 219:449–458. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kaminska B, Kocyk M and Kijewska M: TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol. 986:171–187. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yang XJ, Chen GL, Yu SC, Xu C, Xin YH, Li TT, Shi Y, Gu A, Duan JJ, Qian C, et al: TGF-beta1 enhances tumor-induced angiogenesis via JNK pathway and macrophage infiltration in an improved zebrafish embryo/xenograft glioma model. Int Immunopharmacol. 15:191–198. 2013. View Article : Google Scholar : PubMed/NCBI
19	Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH and Pech M: PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 125:917–928. 1994. View Article : Google Scholar : PubMed/NCBI
20	Cumpanas AA, Cimpean AM, Ferician O, Ceausu RA, Sarb S, Barbos V, Dema A and Raica M: The involvement of PDGF-B/PDGFRβ axis in the resistance to antiangiogenic and antivascular therapy in renal cancer. Anticancer Res. 36:2291–2295. 2016.PubMed/NCBI
21	Xiong B, Gong LL, Zhang F, Hu MB and Yuan HY: TGF beta1 expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol. 8:496–498. 2002. View Article : Google Scholar : PubMed/NCBI
22	Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, et al: PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 18:100–110. 2011. View Article : Google Scholar : PubMed/NCBI